ReviewRecent patents on CNS drug discovery2010
Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation.
Review in Recent patents on CNS drug discovery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 70 citations in OpenAlex.
- P2X7 Receptor in Rare Diseases: Shared Molecular Mechanisms and Therapeutic Implications.Journal of inflammation research · 2026Review
- A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Insight into the pathophysiological advances and molecular mechanisms underlying cerebral stroke: current status.Molecular biology reports · 2024Review
- A Hybrid Approach Combining Shape-Based and Docking Methods to Identify Novel Potential P2X7 Antagonists from Natural Product Databases.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- P2XFrontiers in cellular neuroscience · 2021Review
- A new insight into purinergic pharmacology: Three fungal species as natural P2X7R antagonists.Phytotherapy research : PTR · 2019Article
- The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?Frontiers in pharmacology · 2018Review
- P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy.The Journal of biological chemistry · 2017Article
- P2X7 Participates in Intracerebral Hemorrhage-Induced Secondary Brain Injury in Rats via MAPKs Signaling Pathways.Neurochemical research · 2017Article
- P2X ion channel receptors and inflammation.Purinergic signalling · 2016Review
- Crosstalk between purinergic receptors and canonical signaling pathways in the mouse salivary gland.Cell calcium · 2015Article
- Hydrogen sulfide intervention in focal cerebral ischemia/reperfusion injury in rats.Neural regeneration research · 2015Article
- Pathological pain and the neuroimmune interface.Nature reviews. Immunology · 2014Review
- Natural compounds with P2X7 receptor-modulating properties.Purinergic signalling · 2014Article
- The P2X7 receptor: a key player in immune-mediated bone loss?TheScientificWorldJournal · 2014Review
- P2X7 receptor activation regulates microglial cell death during oxygen-glucose deprivation.Neuropharmacology · 2013Article
- Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain.Molecules (Basel, Switzerland) · 2013Review
- P2X(7) receptors in cerebral ischemia.Neuroscience bulletin · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Inflammation arises in the CNS from a number of neurodegenerative and oncogenic disorders, as well as from ischemic and traumatic brain injuries. These pathologies give rise to increased levels of extracellular adenine nucleotides which, via activation of a variety of cell surface P2 purinergic receptors, influence the inflammatory activities of responding immune cells. One P2 receptor subtype in particular, the P2X(7) receptor, potentiates the release of pro-inflammatory cytokines, such as interleukin-1beta (IL-1beta) from macrophage-like cells. It is also thought to contribute to secondary brain injury by inducing neuronal cell death. Therefore, antagonism of this receptor could have significant therapeutic impact on all disorders, not just CNS, to which excessive inflammatory activities contribute. The use of currently available P2X(7) receptor antagonists for the treatment of CNS inflammation has been limited to the generally non-selective antagonists PPADS, oxidized ATP, Brilliant Blue G, suramin, calmidizolium, and KN-62. However, the recent patents and development of novel P2X(7) receptor antagonists, as discussed in this review, will provide new tools both for clinical and research purposes. Here we discuss compounds for which patents have been applied since 2006, from the following categories: benzamide inhibitors, bicycloheteroaryl compounds, acylhdranzine antagonists, biaromatic P2X(7) antagonists, heterocyclic compounds and amide derivatives, and aromatic amine antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.